Company intelligence / Profile preview

Grey Matter Neurosciences

Toronto, Ontario, Canadagreymatterneurosciences.com ↗

Ownership: Private
Development stage: Preclinical

Overview

Grey Matter Neurosciences is developing a portable, non-invasive focused ultrasound headset designed to stimulate specific brain regions implicated in cognitive decline. The company has secured $14 million in seed financing to advance this device into clinical trials for patients with Alzheimer’s disease. Early-stage research aims to establish safety and feasibility, with the goal of sustainably improving cognitive performance such as memory and concentration. No published human efficacy results yet; first-in-human studies are being initiated

Therapeutic areas: Neurology
Modalities: DeviceNon-pharmacological therapy (Focused ultrasound neuromodulation)
Industry: Therapeutic Medical Devices

Partnerships

Sunnybrook Research Institute (technology licensor)

Beyond the preview

Go deeper on Grey Matter Neurosciences.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Grey Matter Neurosciences.

Explore the full profile